


Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation

Supplementary Material



Supplemental Figure 1. **A**, GSEA on stage I colon carcinomas versus adenomas using a human colon SC signature [55]. **B-G**, GSEA on human stage I colon carcinomas stratified to *LGR5*, *KRAS* and combined *LGR5/KRAS* status as indicated using the colon SC (**B**, **C**), embryonic SC-like (**D-F**) and intestinal SC (**G**) signatures. ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate. **H**, Representative dark field images of *in situ* hybridization with ^{33}P -probe specific for human *LGR5* mRNA and their corresponding H&E stainings showing specific *LGR5*⁺ intestinal SC localization to the hyperplastic crypt bases of human colon adenoma and normal small intestine, respectively.

Supplemental Table 1. List of the genes in the embryonic SC-like, embryonic SC-like minus proliferation and *MYC*-related target genes, intestinal SC and EMT gene signatures used in GSEA.

Supplemental Table 2. List of the top 80 *KRAS*^{mut} leading-edge genes enriched in the embryonic SC-like gene signature from GSEA of lenti-*KRAS*^{mut} versus lenti-pCCL SW48 cells.

Supplemental Table 3. The median and mean *LGR5* mRNA expression levels in normal and malignant human tissues.